...
首页> 外文期刊>Cancer Medicine >Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma
【24h】

Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma

机译:MMP9活性水平在切除的ⅠB期肺腺癌中的预后价值

获取原文

摘要

Abstract The clinical outcomes of patients with early-stage non-small cell lung cancer (NSCLC) have remained unsatisfactory after complete surgical resection. The objective of this study was to explore the prognostic value of matrix metalloproteinase 9 (MMP9) activity level in Chinese patients with stage I B lung adenocarcinoma. A sensitive and validated method was employed for determining the activity of MMP9 in human lung adenocarcinoma cells in vitro. Then, the association was examined between the level of MMP9 enzymatic activity and clinical outcomes. A total of 104 cases were stratified according to the IASLC/ATS/ERS classification scheme and activity of MMP9 was analyzed by SensoLyte???? assay kit. The results showed that the MMP9 activity was the highest in solid predominant and micropapillary predominant subtypes, intermediate in acinar predominant and papillary predominant subtypes, and the lowest in lepidic predominant subtype. Multivariate analysis revealed that pathological subtype and activity of MMP9 were independent prognostic factors for disease-free survival (DFS), respectively ( P = 0.005 and 0.029). Significant relationship existed between enzyme activity of MMP9 and prognosis. And the 30 months DFS of high- and low-level MMP9 activity tumors was 44.2% and 84.1% ( P < 0.0001), respectively. High-level MMP9 activity is correlated with aggressive tumor behaviors and poor clinical outcomes in early-stage lung adenocarcinoma after complete resection.
机译:摘要早期非小细胞肺癌(NSCLC)患者在完全手术切除后的临床效果仍然不理想。这项研究的目的是探讨基质金属蛋白酶9(MMP9)活性水平在中国ⅠB期肺腺癌患者中的预后价值。采用一种敏感且经过验证的方法来测定人肺腺癌细胞中MMP9的活性。然后,检查了MMP9酶活性水平与临床结果之间的关联。根据IASLC / ATS / ERS分类方案对104例患者进行分层,并用SensoLyte分析MMP9的活性。检测试剂盒。结果表明,MMP9活性在固态优势型和微乳头优势型中最高,在腺泡优势型和乳头优势型中居中间,而在鳞状优势型中最低。多变量分析显示,MMP9的病理亚型和活性分别是无病生存(DFS)的独立预后因素(P = 0.005和0.029)。 MMP9的酶活性与预后之间存在显着的关系。高和低水平MMP9活性肿瘤的30个月DFS分别为44.2%和84.1%(P <0.0001)。完全切除后,早期肺腺癌中高水平的MMP9活性与侵略性肿瘤行为和不良的临床预后相关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号